Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2003. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically regarding transactions by the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share purchase transactions for employee benefit plans.
- Share Purchase Price: GBP 11.985 per share.
- Shares Purchased (SmithKline Beecham Bonus Investment Plan): 1,474 Ordinary shares.
- Shares Purchased (GlaxoSmithKline Annual Investment Plan): 4,437 Ordinary shares.
- Total Shares Purchased: 5,911 Ordinary shares.
Material Changes
The filing details the acquisition of Ordinary shares by the SmithKline Beecham Employee Benefit Trust on July 10, 2003. These purchases were made for participants in two specific investment plans. The document notes that Directors Dr. J.P. Garnier and John Coombe hold an interest in these shares as potential beneficiaries of the discretionary fund, similar to other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine disclosure of director interests.
Key Facts for Investor Verification
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the aggregate interest of directors Dr. J.P. Garnier and John Coombe.
- Confirm the current market price of GlaxoSmithKline Ordinary Shares relative to the GBP 11.985 purchase price cited in this 2003 filing.
- Review subsequent filings to determine if the discretionary fund status or director interests have changed since July 2003.